Fig. 7

JMJD2A activates PDK1 to regulate Akt-mTOR signaling. a JMJD2A expression is correlated with PDK1 expression in glioma tissues based on the TGCA database. b JMJD2A knockdown reduces PDK1 expression in U87MG cells. U87MG cells were infected with lentivirus expressing sh-ctrl or sh-JMJD2A for 48 h. **p < 0.01. c JMJD2A overexpression promotes PDK1 expression in U87MG cells. U87MG cells were infected with lentivirus expressing ctrl or JMJD2A for 48 h. **p < 0.01. d Chromatin immunoprecipitation assay demonstrates the enrichment of JMJD2A on the PDK1 promoter in U87MG cells. **p < 0.01. e Chromatin immunoprecipitation assay demonstrates the enrichment of H3K9me3 and H3K36me3 n the PDK1 promoter in U87MG cells. **p < 0.01. f JMJD2A knockdown increases the enrichment of H3K9me3 and H3K36me3 at PDK1 promoter in U87MG cells. U87MG cells were infected with lentivirus for 48 h. **p < 0.01. g JMJD2A overexpression reduces the enrichment of H3K9me3 and H3K36me3 at PDK1 promoter in U87MG cells. U87MG cells were infected with lentivirus for 48 h. **p < 0.01. h Inhibition of PDK1 with OSU-03012 blocks JMJD2A-mediated activation of Akt-mTOR signaling. The U87MG cells with/without JMJD2A overexpression were treated with OSU-03012 (1 μM) for 24 h. i Inhibition of PDK1 with OSU-03012 blocks JMJD2A-mediated effects on the proliferation of U87MG cells. U98MG with/without JMJD2A overexpression were treated with OSU-03012 (1 μM)